Usefulness of detection of complement activation products in evaluating SLE activity

Abstract

Complement activation products, such as C1rs-C1inh, specific for the activation of the classical pathway, C3b(Bb)P, specific for the activation of the alternative pathway and SC5b-9, specific for common terminal pathway of the complement cascade, were measured in healthy donors and in patients with clinically active and inactive systemic lupus erythematosus (SLE). Plasma levels of C3b(Bb)P and SC5b-9 were moderately, those of C1rs-C1inhibitor (C1rs-C1inh) were markedly elevated in patients with clinically inactive SLE, compared with healthy controls. The difference between active and inactive stages of the disease was best reflected by C3b(Bb)P plasma concentration (P < 0.001), which also showed the highest correlation with the SLEDAI (Rs = 0.41 P < 0.001) and which was the most useful in distinguishing active and inactive sample pairs as well. The difference between SC5b-9 levels in the active and inactive stages was also significant (P = 0.007), while that of C1rs-C1inh did not differ significantly (P = 0.136). The correlation of the SLEDAI with SC5b-9 was 0.3 (P = 0.015), while with C1rs-C1inh it was 0.21 (P = 0.089). These findings suggest that the measurement of complement activation products, especially that of the alternative pathway, are sensitive markers of the activity of SLE and can be used for clinical purposes.

Keywords

C3b(Bb)P C1rs-C1inh SC5b-9 SLE activity

Get full access to this article

View all access options for this article.

References

IUIS/WHO Working Group . Use and abuse of eight widely-used diagnostic procedures in clinical immunology: a WHO memorandum . Bull WHO 1981; 59: 717–728 .

Milis L , Timmermans V , Morris CA , Pussel BA , Charlesworth JA . The value of complement measurements in the assessment of lupus activity . Aust N Z J Med 1992; 22: 338–344 .

Valentijn RM , van Overhagen H , Hazevoet HM et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus . Arthritis Rheum 1985; 28: 904–913 .

Senaldi G , Makinde VA , Vergani D , Isenberg DA . Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus . Ann Rheum Dis 1988; 47: 913–917 .

Kolb WP , Morrow RP , Tamerius JD . Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples . Complement Inflamm 1989; 6: 175–204 .

Abramson SB , Buyon JP . Activation of the complement pathway: comparison of normal pregnancy, prreclampsi, and systemic lupus erythematosus during pregnancy . Am J Reprod Immunol 1992; 28: 183–187 .

Kerr LD , Adelsberg BR , Schulman P , Spiera H . Factor B activation products in patients with systemic lupus erythematosus . Arthritis Rheum 1989; 32: 1406–1413 .

Buyon JP , Tamerius J , Belmont HM , Abramson SB . Assessment of disease activity and impending flare in patients with systemic lupus erythematosus . Arthritis Rheum 1992; 35: 1028–1037 .

Buyon JP , Tamerius J , Ordorica S , Young B , Abramson SB . Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy . Arthritis Rheum 1992; 35: 55–61 .

10.

Manzi S , Rairie JE , Carpenter AB et al. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity . Arthritis Rheum 1996; 39: 1178–1788 .

11.

Porcel JM , Ordi J , Castro-Salomo A et al. The value of complement activation products in the assessment of systemic lupus erythematosus flares . Clin Immunol Immunopathol 1995; 74: 283–288 .